TMTim R. Mercer

Tim R. Mercer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tim R. Mercer has a total of 448 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An HLA Association With COVID-19 Vaccine Reactogenicity Correlates With Fewer SARS-CoV-2 Infections and Monocyte Activation

    by Jill Hollenbach, Anshika Srivastava, Demetra Chatzileontiadou, Anurag Adhikari, Rayo Suseno, Sean Lin, Juliano Boquett, Jamie Tuibeo, Tasneem Yusufali, Noah Peyser, et al.

    Vaccination against SARS-CoV-2 has been the most effective tool in mitigating the COVID-19 pandemic. However, some individuals experience side effects that cause distress and interfere with daily activities, which can limit vaccine uptake, with important public health implications. Here, we considered the impact of HLA variation on the propensity for mild side effects with COVID-19 vaccination. We examined variation in HLA-A, -B, -C, -DRB1, and -DQB1 for association with self-reported side effects in a large cohort of U.S. Euro-ancestry vaccinated individuals (N = 50,535) and confirmed results in an independent replication cohort (N = 4,575). We found that HLA-A*03:01 was significantly associated with systemic side effects (OR = 1.36, CI = 1.31-1.41, p = 6.79×10-57) and fewer breakthrough infections, and that this phenomenon is specific to the COVID-19 vaccine. Surprisingly, we observed limited activation of CD8+ T cells in HLA-A*03:01+ samples to the Spike-derived peptides, excluding them as a likely source of the reported vaccine side effects. Rather, examination of immune cell subsets, prior and after vaccination, points to a central role for monocytes in the production of IL-6 and IL-8, which significantly correlates with the reported severity of side effects in HLA-A*03:01+ donors. Meanwhile, the large, mostly naïve, and low-affinity population of Spike-specific CD8+ T cells likely contribute to an inflammatory milieu in HLA-A*03:01 carriers through weak binding to antigen presenting cells. This work sheds light on the mechanisms underlying HLA-mediated COVID-19 vaccine reactogenicity and associated reduction in infections, providing important new insights that may support efforts to optimize vaccine efficacy and promote broader public involvement in vaccination programs.


  • The design, manufacture and LNP formulation of mRNA for research use

    by Laura J. Leighton, Natasha Chaudhary, Hannah T. Tompkins, Abhishek Kulkarni, Nissa L. Carrodus, Magdalena A. Budzinska, Sneha Lakshman Das, Seth W. Cheetham, Tim R. Mercer

    The delivery of mRNA provides a versatile platform to achieve rapid and robust protein expression within cells. mRNA delivery has therefore been widely adopted in research, and mRNA medicines are now being developed to treat a range of diseases. However, high-quality mRNA must be produced to ensure the safety, performance and effectiveness of these medicines. Here, we provide a validated, end-to-end protocol describing the production of mRNA for research and preclinical use. This protocol includes primary sequence design, DNA template production, mRNA synthesis by in vitro transcription, formulation into lipid nanoparticles and transfection into cultured cells. Each step is supported by a range of quality control tests to analyze mRNA integrity and purity and is illustrated with example results to provide information about expected performance. The protocol prioritizes simple production steps that are suitable for small-scale mRNA manufacture, such as PCR preparation of the DNA template, and that can be performed within a laboratory and avoid specialized equipment. The protocol produces high-quality mRNA that can be used for in vitro and in vivo preclinical studies, including for vaccine, protein and gene- and cell-therapy applications. Together, this provides a fast and reliable protocol to produce high-quality mRNA suitable for laboratory research and preclinical development.


  • Open Access

    Ageing-Related Changes to H3K4me3, H3K27ac, and H3K27me3 in Purified Mouse Neurons

    by Brandon Signal, Andrew J. Phipps, Katherine A. Giles, Shannon N. Huskins, Timothy R. Mercer, Mark D. Robinson, Adele Woodhouse, Phillippa C. Taberlay

    Neurons are central to lifelong learning and memory, but ageing disrupts their morphology and function, leading to cognitive decline. Although epigenetic mechanisms are known to play crucial roles in learning and memory, neuron-specific genome-wide epigenetic maps into old age remain scarce, often being limited to whole-brain homogenates and confounded by glial cells. Here, we mapped H3K4me3, H3K27ac, and H3K27me3 in mouse neurons across their lifespan. This revealed stable H3K4me3 and global losses of H3K27ac and H3K27me3 into old age. We observed patterns of synaptic function gene deactivation, regulated through the loss of the active mark H3K27ac, but not H3K4me3. Alongside this, embryonic development loci lost repressive H3K27me3 in old age. This suggests a loss of a highly refined neuronal cellular identity linked to global chromatin reconfiguration. Collectively, these findings indicate a key role for epigenetic regulation in neurons that is inextricably linked with ageing.


  • Open Access

    Blood collection tube and RNA purification method recommendations for extracellular RNA transcriptome profiling: A large-scale pre-analytical variable performance evaluation

    by Jo Vandesompele, Jasper Anckaert, Francisco Avila Cobos, Katleen De Preter, Olivier De Wever, Jilke De Wilde, Anneleen Decock, Philippe Decruyenaere, Jill Deleu, Bert Dhondt, et al.

    Using blood-based extracellular RNA (circulating cell-free RNA; exRNA) as a clinical biomarker requires validated procedures for sample collection and processing and RNA quantification. No study to date has systematically tested pre-analytical variables affecting transcriptome-wide exRNA analysis. We evaluated and compared ten blood collection tubes, three time intervals between blood draw and blood processing, and eight RNA purification methods using the supplier-specified minimal and maximal biofluid input volumes. The impact on deep transcriptome profiling of both microRNAs and messenger RNAs in blood plasma or serum was separately assessed for each pre-analytical variable and for interactions among a selected pre-analytical variable set, resulting in 456 complete extracellular transcriptomes. The processing and analysis workflow was controlled using 189 synthetic spike-in RNA molecules. In blood collection tube comparisons, manufacturer-designated preservation tubes did not stabilize exRNA well, causing variations in RNA concentration and number of detected genes over time, together with increased replicate variability. We also document large performance differences in RNA purification methods, affecting detected gene number, replicate variability and observed transcriptome complexity, and demonstrate technical interactions between certain blood collection tubes, purification methods and time intervals. Our results are comprehensively summarized in 11 analytical performance metrics that enable an informed selection of the best sample processing workflow for a given experiment. We provide robust quality control metrics for exRNA quantification methods with validated standard operating procedures (SOPs), and put forward recommendations for both users and manufacturers of RNA purification methods and blood collection tubes, collectively, essential groundwork for future exRNA-based precision medicine applications.


  • Open Access

    A universal molecular control for DNA, mRNA and protein expression

    by Helen M. Gunter, Scott E. Youlten, Andre L. M. Reis, Tim McCubbin, Bindu Swapna Madala, Ted Wong, Igor Stevanovski, Arcadi Cipponi, Ira W. Deveson, Nadia S. Santini, et al.

    The expression of genes encompasses their transcription into mRNA followed by translation into protein. In recent years, next-generation sequencing and mass spectrometry methods have profiled DNA, RNA and protein abundance in cells. However, there are currently no reference standards that are compatible across these genomic, transcriptomic and proteomic methods, and provide an integrated measure of gene expression. Here, we use synthetic biology principles to engineer a multi-omics control, termed pREF, that can act as a universal molecular standard for next-generation sequencing and mass spectrometry methods. The pREF sequence encodes 21 synthetic genes that can be in vitro transcribed into spike-in mRNA controls, and in vitro translated to generate matched protein controls. The synthetic genes provide qualitative controls that can measure sensitivity and quantitative accuracy of DNA, RNA and peptide detection. We demonstrate the use of pREF in metagenome DNA sequencing and RNA sequencing experiments and evaluate the quantification of proteins using mass spectrometry. Unlike previous spike-in controls, pREF can be independently propagated and the synthetic mRNA and protein controls can be sustainably prepared by recipient laboratories using common molecular biology techniques. Together, this provides a universal synthetic standard able to integrate genomic, transcriptomic and proteomic methods.


  • Expression of Long Noncoding RNAs During Mouse Development

    by Timothy Mercer

    The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.

  • Open Access

    mRNA vaccine quality analysis using RNA sequencing

    by Helen M. Gunter, Senel Idrisoglu, Swati Singh, Dae Jong Han, Emily Ariens, Jonathan R. Peters, Ted Wong, Seth W. Cheetham, Jun Xu, Subash Kumar Rai, et al.

    The success of mRNA vaccines has been realised, in part, by advances in manufacturing that enabled billions of doses to be produced at sufficient quality and safety. However, mRNA vaccines must be rigorously analysed to measure their integrity and detect contaminants that reduce their effectiveness and induce side-effects. Currently, mRNA vaccines and therapies are analysed using a range of time-consuming and costly methods. Here we describe a streamlined method to analyse mRNA vaccines and therapies using long-read nanopore sequencing. Compared to other industry-standard techniques, VAX-seq can comprehensively measure key mRNA vaccine quality attributes, including sequence, length, integrity, and purity. We also show how direct RNA sequencing can analyse mRNA chemistry, including the detection of nucleoside modifications. To support this approach, we provide supporting software to automatically report on mRNA and plasmid template quality and integrity. Given these advantages, we anticipate that RNA sequencing methods, such as VAX-seq, will become central to the development and manufacture of mRNA drugs.


  • Open Access

    Library adaptors with integrated reference controls improve the accuracy and reliability of nanopore sequencing

    by Helen M. Gunter, Scott E. Youlten, Bindu Swapna Madala, Andre L. M. Reis, Igor Stevanovski, Ted Wong, Sarah K. Kummerfield, Ira W. Deveson, Nadia S. Santini, Esteban Marcellin, et al.

    Library adaptors are short oligonucleotides that are attached to RNA and DNA samples in preparation for next-generation sequencing (NGS). Adaptors can also include additional functional elements, such as sample indexes and unique molecular identifiers, to improve library analysis. Here, we describe Control Library Adaptors, termed CAPTORs, that measure the accuracy and reliability of NGS. CAPTORs can be integrated within the library preparation of RNA and DNA samples, and their encoded information is retrieved during sequencing. We show how CAPTORs can measure the accuracy of nanopore sequencing, evaluate the quantitative performance of metagenomic and RNA sequencing, and improve normalisation between samples. CAPTORs can also be customised for clinical diagnoses, correcting systematic sequencing errors and improving the diagnosis of pathogenic BRCA1/2 variants in breast cancer. CAPTORs are a simple and effective method to increase the accuracy and reliability of NGS, enabling comparisons between samples, reagents and laboratories, and supporting the use of nanopore sequencing for clinical diagnosis.


  • The potential of long noncoding RNA therapies

    by Tim R. Mercer, Trent Munro, John S. Mattick


  • Open Access

    A clinical laboratory–developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia

    by Stanley W. K. Ng, Tracy Murphy, Ian King, Tong Zhang, Michelle Mah, Zhibin Lu, Natalie Stickle, Narmin Ibrahimova, Andrea Arruda, Amanda Mitchell, et al.

    Leukemia stem cells (LSCs) are linked to relapse in acute myeloid leukemia (AML). The LSC17 gene expression score robustly captures LSC stemness properties in AML and can be used to predict survival outcomes and response to therapy, enabling risk-adapted, upfront treatment approaches. The LSC17 score was developed and validated in a research setting. To enable widespread use of the LSC17 score in clinical decision making, we established a laboratory-developed test (LDT) for the LSC17 score that can be deployed broadly in clinical molecular diagnostic laboratories. We extensively validated the LSC17 LDT in a College of American Pathologists/Clinical Laboratory Improvements Act (CAP/CLIA)-certified laboratory, determining specimen requirements, a synthetic control, and performance parameters for the assay. Importantly, we correlated values from the LSC17 LDT to clinical outcome in a reference cohort of patients with AML, establishing a median assay value that can be used for clinical risk stratification of individual patients with newly diagnosed AML. The assay was established in a second independent CAP/CLIA-certified laboratory, and its technical performance was validated using an independent cohort of patient samples, demonstrating that the LSC17 LDT can be readily implemented in other settings. This study enables the clinical use of the LSC17 score for upfront risk-adapted management of patients with AML.